Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Agence France Presse (12.07.07) - Thursday, December 20, 2007
British researchers examined data on 7,916 HIV patients taking the standard three-drug cocktail of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. They found that 167 had developed extensive resistance to all three drug classes. The study population had a 9.2 percent chance of developing three- drug resistance after 10 years, the authors reported.
The study's findings are particularly welcome news for the developing world. When primary treatment fails, doctors must turn to second- and third-line drugs. In resource-poor locales, these are much more expensive and difficult to obtain. "In such settings, only one or two regimes are normally available, which results in disastrous consequences when these regimes fail," according to a commentary published with the study.
The news, however, comes with caveats:
*While the British patients typically started therapy early, the rate of failure was higher for those who started treatment after their CD4 cell levels fell below 200. In developing nations, AIDS drugs are rarely administered before CD4 cells fall below 200.
*Among patients who failed on the three-drug cocktail, 90 percent showed resistance to seven first-line drugs, and 58 percent of those failed on second-line therapies as well.
The full report, "Risk of Extensive Virological Failure to the Three Original Antiretroviral Drug Classes over Long-Term Follow-up from the Start of Therapy in Patients with HIV Infection: An Observational Cohort Study," and the commentary, "A Wake-Up Call for Global Access to Salvage HIV Drug Regimens," were published in The Lancet (2007;370(9603):1923- 1928 and 1885-1887).
071220
AD072656
Copyright © 2007 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.